Evidence map›Paper›PMID 40336316›Full record

ArticleHaematologica2025

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Jonathan A Webster, Madison Reed, Hua-Ling Tsai, Philip H Imus, Douglas B Smith, Alexander J Ambinder, Mark J Levis, Amy E DeZern, Gabrielle T Prince, Tania Jain and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jonathan A WebsterDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD. Jwebst17@jhmi.edu.
Madison ReedDepartment of Internal Medicine, Yale University, New Heaven, CT.
Hua-Ling TsaiDivision of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Philip H ImusDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Douglas B SmithDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Alexander J AmbinderDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Mark J LevisDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Amy E DeZernDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Gabrielle T PrinceDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Tania JainDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Javier Bolaños-MeadeDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Lukasz P GondekDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Gabriel GhiaurDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
William Brian DaltonDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Theodoros KarantanosDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Suman PaulDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Ephraim J FuchsDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Cole SterlingDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Lode J SwinnenDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Nina Wagner-JohnstonDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Richard F AmbinderDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Christian B GockeDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Syed Abbas AliDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Carol Ann HuffDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Leo LuznikDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX.
Ravi VaradhanDivision of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Richard J JonesDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.
Ivana GojoDivision of Hematologic Malignancy, Department of Oncology, Johns Hopkins University, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic landscape in acute lymphoblastic leukemia (ALL) has changed dramatically over the last decade. Allogeneic blood or marrow transplantation (alloBMT) has also evolved and remains an important option for consolidation. We assessed the interplay between these factors by analyzing the outcomes of 251 adult ALL (214 B- and 37 T-ALL) patients undergoing alloBMT with post-transplantation cyclophosphamide across two eras: 2008-2014 (ERA1) and 2015-2022 (ERA2). ERA1 patients were younger (median age 45.5 years vs. 50 years, P=0.03), less likely to have a Hematopoietic Stem Cell Transplant-Comorbidity Index score ≥4 (9% vs. 21%, P=0.01), more likely to have measurable residual disease by flow cytometry (20% vs. 9%, P=0.01), and receive myeloablative conditioning (56% vs. 3%, P<0.0001). Overall survival (OS) (Hazard Ratio [HR]: 0.54, P=0.005), relapse-free survival (RFS) (HR: 0.52, P=0.001), and relapse (HR: 0.45, P=0.0005) were improved in ERA2. Non-relapse mortality was similar between eras (HR: 0.88, P=0.73). Significant improvements in OS (HR 0.49, P=0.004) and RFS (HR: 0.46, P=0.0004) in ERA2 due to fewer relapses (HR: 0.38, P=0.0003) were restricted to patients with B-ALL. Irrespective of era, B-ALL patients transplanted in first remission (CR1) had improved RFS (HR: 0.40, P=0.05) if they received pre-transplant blinatumomab. Similarly, Philadelphia chromosome-positve ALL patients transplanted in CR1 who received 2nd or 3rd generation tyrosine kinase inhibitors at diagnosis had improved RFS (HR: 0.29, P=0.0004) and reduced relapse (HR: 0.23, P=0.002) compared to those who received imatinib. Improved alloBMT outcomes in ERA2 in spite of older patient age, increased co-morbidities, and less intensive conditioning were due to reductions in relapse likely driven by changes in pre-transplant therapy.

Indexed as

Bone Marrow TransplantationCyclophosphamideHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesTransplantation ConditioningTransplantation, HomologousTreatment OutcomeCyclophosphamide

Identifiers

PMID40336316
PMCPMC12580691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.